Roche: new data supports Esbriet safety profile.
(CercleFinance.com) - Roche said on Tuesday that a new six-month study showed that combining Esbriet with Boehringer Ingelheim's nintedanib in patients with idiopathic pulmonary fibrosis had a similar safety profile to that expected for each treatment alone.
A second analysis suggested that treatment with Esbriet may be associated with a reduction of multiple progression events, as well as reduction of deaths after one or more progression events, the Swiss drugmaker said.
Finally, a third study based on real-world data, where over 1,000 European patients were analysed, showed that no new safety signals were observed.
Around 100,000 people in the United States and 110,000 people in Europe have IPF, a fatal disease caused by irreversible, progressive scarring of the lungs, which makes breathing difficult.
As a reminder, oral Esbriet is approved for the treatment of IPF in approximately 40 countries worldwide.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
A second analysis suggested that treatment with Esbriet may be associated with a reduction of multiple progression events, as well as reduction of deaths after one or more progression events, the Swiss drugmaker said.
Finally, a third study based on real-world data, where over 1,000 European patients were analysed, showed that no new safety signals were observed.
Around 100,000 people in the United States and 110,000 people in Europe have IPF, a fatal disease caused by irreversible, progressive scarring of the lungs, which makes breathing difficult.
As a reminder, oral Esbriet is approved for the treatment of IPF in approximately 40 countries worldwide.
Copyright (c) 2017 CercleFinance.com. All rights reserved.